{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:59:41Z","timestamp":1791489581265,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":251,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101440","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:10:05Z","timestamp":1789506605000},"page":"101440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Racial and ethnic disparities in metabolic syndrome care among prostate cancer patients on androgen deprivation therapy"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3045-6813","authenticated-orcid":false,"given":"Yazan K.","family":"Barqawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-7882","authenticated-orcid":false,"given":"Krishna Rekha","family":"Moturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6438-4192","authenticated-orcid":false,"given":"Neda","family":"Hashemi-Sadraei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1314-4906","authenticated-orcid":false,"given":"Melissa H.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1505-205X","authenticated-orcid":false,"given":"Todd A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7635-8567","authenticated-orcid":false,"given":"Mohammad T.","family":"Alashqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7068-8029","authenticated-orcid":false,"given":"Matthew E.","family":"Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101440_bib0001","unstructured":"Centers for Disease Control and Prevention. United States Cancer Statistics Data Visualizations Tool. Atlanta, GA: U.S. Department of Health and Human Services; [cited 2025 May 12]. Available from: https:\/\/www.cdc.gov\/united-states-cancer-statistics\/dataviz\/."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101440_bib0002","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101440_bib0003","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101440_bib0004","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101440_bib0005","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101440_bib0006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","article-title":"Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials","volume":"79","author":"Abufaraj","year":"2021","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101440_bib0007","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101440_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11886-021-01561-9","article-title":"Cardiovascular toxicity of androgen deprivation therapy","volume":"23","author":"Boland","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101440_bib0009","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/cancers15082316","article-title":"Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer","volume":"15","author":"Fradin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101440_bib0010","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jaccao.2024.08.004","article-title":"Body composition during androgen deprivation therapy in prostate cancer: a target to reduce cardiovascular risk","volume":"6","author":"Lee","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101440_bib0011","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101440_bib0012","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/BF00403180","article-title":"Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome","volume":"34","author":"Ferrannini","year":"1991","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101440_bib0013","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/diab.41.6.715","article-title":"Prospective analysis of the insulin-resistance syndrome (syndrome X)","volume":"41","author":"Haffner","year":"1992","journal-title":"Diabetes"},{"issue":"9468","key":"10.1016\/j.ctarc.2026.101440_bib0014","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"issue":"5\u20136","key":"10.1016\/j.ctarc.2026.101440_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A comprehensive definition for metabolic syndrome","volume":"2","author":"Huang","year":"2009","journal-title":"Dis. Model. Mech."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101440_bib0016","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2164\/jandrol.108.005454","article-title":"Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth","volume":"29","author":"Basaria","year":"2008","journal-title":"J. Androl."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101440_bib0017","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101440_bib0018","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-16-0200","article-title":"Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer","volume":"175","author":"Cheung","year":"2016","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101440_bib0019","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.2013.49.5523","article-title":"Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review","volume":"32","author":"Gardner","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101440_bib0020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/andr.12731","article-title":"Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review","volume":"8","author":"Liang","year":"2020","journal-title":"Andrology"},{"issue":"27","key":"10.1016\/j.ctarc.2026.101440_bib0021","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101440_bib0022","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101440_bib0023","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.5489\/cuaj.6685","article-title":"Optimizing screening and management of cardiovascular health in prostate cancer: a review","volume":"14","author":"Kenk","year":"2020","journal-title":"Can. Urol. Assoc. J."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101440_bib0024","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101440_bib0025","first-page":"1","article-title":"Screening and treatment of cardiovascular comorbidities among patients with prostate cancer who start androgen deprivation therapy","volume":"27","author":"Castro-Alonso","year":"2019","journal-title":"Support. Care Cancer"},{"issue":"Supplement 4","key":"10.1016\/j.ctarc.2026.101440_bib0026","first-page":"e178","article-title":"PD09-11 Cardiovascular risk factors for patients with advanced prostate cancer on androgen deprivation therapy","volume":"203","author":"Gan","year":"2020","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101440_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0070","article-title":"Assessment and management of cardiovascular risk factors among US veterans with prostate cancer","volume":"4","author":"Sun","year":"2021","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.ctarc.2026.101440_bib0028","unstructured":"UNM Comprehensive Cancer Center | Albuquerque, New Mexico. UNM Health. Accessed August 9, 2026. https:\/\/unmhealth.org\/locations\/cancer-center.html."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101440_bib0029","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","article-title":"Cancer health disparities in racial\/ethnic minorities in the United States","volume":"124","author":"Zavala","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101440_bib0030","first-page":"111","article-title":"Cancer statistics for African American and Black people, 2025","volume":"75","author":"Saka","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101440_bib0031","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2105\/AJPH.90.10.1595","article-title":"Knowledge, attitudes, and screening practices among older men regarding prostate cancer","volume":"90","author":"Steele","year":"2000","journal-title":"Am. J. Public. Health"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101440_bib0032","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cncr.21673","article-title":"A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma","volume":"106","author":"Spencer","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101440_bib0033","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2009.26.2469","article-title":"Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE","volume":"28","author":"Moses","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101440_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1255","article-title":"Association of sociodemographic and health-related factors with receipt of nondefinitive therapy among younger men with high-risk prostate cancer","volume":"3","author":"Bagley","year":"2020","journal-title":"JAMA Netw. Open."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101440_bib0035","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.eururo.2016.08.047","article-title":"Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer","volume":"71","author":"Gray","year":"2017","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101440_bib0036","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jamaoncol.2015.3384","article-title":"Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer","volume":"2","author":"Schmid","year":"2016","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101440_bib0037","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1037\/a0028626","article-title":"Prostate cancer screening among ethnically diverse first-degree relatives of prostate cancer cases","volume":"31","author":"Glenn","year":"2012","journal-title":"Health Psychol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101440_bib0038","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/pcan.2013.3","article-title":"Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis","volume":"16","author":"Garg","year":"2013","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ctarc.2026.101440_bib0039","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.5888\/pcd12.150088","article-title":"Prostate cancer Screening among American Indians and Alaska Natives: the Health and Retirement Survey, 1996-2008","volume":"12","author":"Goins","year":"2015","journal-title":"Prev. Chronic Dis."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101440_bib0040","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/PAS.0000000000000656","article-title":"Radical prostatectomy findings in white Hispanic\/Latino men with NCCN very low-risk prostate cancer detected by template biopsy","volume":"40","author":"Kryvenko","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ctarc.2026.101440_bib0041","unstructured":"Haque R, Van Den Eeden SK, Jacobsen SJ, Caan B, Avila CC, Slezak J, Sternfeld B, Loo RK, Quinn VP. Correlates of prostate-specific antigen testing in a large multiethnic cohort. Am. J. Manag. Care. 2009 Nov;15(11):793\u20139. PMID: 19895183. https:\/\/pubmed.ncbi.nlm.nih.gov\/19895183\/."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101440_bib0042","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21101\/cejph.a3622","article-title":"Racial\/ethnic differences in predictors of PSA screening in a tri-ethnic population","volume":"19","author":"Hosain","year":"2011","journal-title":"Cent. Eur. J. Public. Health"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101440_bib0043","first-page":"343","article-title":"Colorectal, prostate, and skin cancer screening among Hispanic and White non-Hispanic men, 2000-2005","volume":"103","author":"Zhou","year":"2011","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.ctarc.2026.101440_bib0044","doi-asserted-by":"crossref","unstructured":"Saylor PJ, Keating NL, Freedland SJ, Smith MR Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011;71(3):255\u2013261. PMID: 21319864; PMCID: PMC3671348. https:\/\/doi.org\/10.2165\/11588930-000000000-00000.","DOI":"10.2165\/11588930-000000000-00000"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101440_bib0045","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/j.clgc.2022.12.006","article-title":"Association of Androgen deprivation therapy with metabolic disease in prostate cancer patients: an updated meta-analysis","volume":"21","author":"Swaby","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101440_bib0046","doi-asserted-by":"crossref","first-page":"163","DOI":"10.6004\/jnccn.2022.7083","article-title":"Androgen deprivation therapy and risk of cardiovascular disease in patients with prostate cancer based on existence of cardiovascular risk","volume":"21","author":"Dragomir","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.ctarc.2026.101440_bib0047","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101440_bib0048","doi-asserted-by":"crossref","first-page":"111","DOI":"10.21037\/atm.2016.02.15","article-title":"Model building strategy for logistic regression: purposeful selection","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101440_bib0049","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0749-3797(99)00041-0","article-title":"Prostate-specific antigen for prostate cancer screening: do physician characteristics affect its use?","volume":"17","author":"Edlefsen","year":"1999","journal-title":"Am. J. Prev. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101440_bib0050","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/pros.22985","article-title":"The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels","volume":"75","author":"Izumi","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.ctarc.2026.101440_bib0051","unstructured":"Hill L, Ndugga N, Artiga S, Damico A Health Coverage by Race and Ethnicity, 2010-2023. Kaiser Family Foundation. Published February 13, 2025. Accessed February 4, 2026. https:\/\/www.kff.org\/racial-equity-and-health-policy\/health-coverage-by-race-and-ethnicity\/."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101440_bib0052","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11532820-000000000-00000","article-title":"Ethnicity\/race, use of pharmacotherapy, scope of physician-ordered cholesterol screening, and provision of diet\/nutrition or exercise counseling during US office-based visits by patients with hyperlipidemia","volume":"10","author":"Willson","year":"2010","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101440_bib0053","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1006\/pmed.2001.0928","article-title":"Disparities in cholesterol screening: falling short of a national health objective","volume":"33","author":"Brown","year":"2001","journal-title":"Prev. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101440_bib0054","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jama.287.10.1288","article-title":"Racial disparities in the quality of care for enrollees in medicare managed care","volume":"287","author":"Schneider","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101440_bib0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11606-016-3913-x","article-title":"Racial and ethnic disparities in diabetes screening between Asian Americans and other adults: BRFSS 2012-2014","volume":"32","author":"Tung","year":"2017","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101440_bib0056","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1186\/s12913-021-07146-0","article-title":"Are racial\/ethnic minorities recently diagnosed with diabetes less likely than white individuals to receive guideline-directed diabetes preventive care?","volume":"21","author":"Marcondes","year":"2021","journal-title":"BMC Health v. Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101440_bib0057","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101440_bib0058","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/met.2008.0021","article-title":"Metabolic syndrome: prevalence among American Indian and Alaska native people living in the southwestern United States and in Alaska","volume":"6","author":"Schumacher","year":"2008","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.ctarc.2026.101440_bib0059","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40985-016-0043-2","article-title":"Hispanic health in the USA: a scoping review of the literature","volume":"37","author":"Velasco-Mondragon","year":"2016","journal-title":"Public. Health Rev."},{"issue":"Suppl 6","key":"10.1016\/j.ctarc.2026.101440_bib0060","doi-asserted-by":"crossref","first-page":"TPS273","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS273","article-title":"A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio)","volume":"41","author":"Hahn","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101440_bib0061","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101440_bib0062","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/17446651.1.1.57","article-title":"Metabolic syndrome and risk for type 2 diabetes","volume":"1","author":"Meigs","year":"2006","journal-title":"Expert. Rev. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101440_bib0063","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of Cardiovascular Disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ctarc.2026.101440_bib0064","unstructured":"Centers for Medicare & Medicaid Services. ICD-10 [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; [cited 2026 Feb 5]. Available from: https:\/\/www.cms.gov\/Medicare\/Coding\/ICD10."},{"key":"10.1016\/j.ctarc.2026.101440_bib0065","article-title":"Icd-9-Cm [Internet]","year":"2026","journal-title":"Baltim. (MD): Cent. Medicare Medicaid Serv."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101440_bib0066","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/CIRCOUTCOMES.115.002043","article-title":"Use of contraindicated antiplatelet medications in the setting of percutaneous coronary intervention: insights from the Veterans Affairs Clinical Assessment, Reporting, and tracking program","volume":"9","author":"Barnes","year":"2016","journal-title":"Circ. Cardiovasc. Qual. Outcomes"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:38:14Z","timestamp":1791488294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":66,"alternative-id":["S2468294226003503"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101440","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial and ethnic disparities in metabolic syndrome care among prostate cancer patients on androgen deprivation therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101440"}}